CUAMC
ATRA icon

China Universal Asset Management Company’s Atara Biotherapeutics ATRA Stock Holding History

China Universal Asset Management Company’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-104
Closed -$3.83K – 434
2023
Q3 		$3.83K Buy
104
+53
+104% +$2.36K ﹤0.01% 405
2023
Q2 		$2.07K Sell
51
-1
-2% -$57 ﹤0.01% 424
2023
Q1 		$3.77K Buy
52
+13
+33% +$1.26K ﹤0.01% 394
2022
Q4 		$3.16K Buy
39
+4
+11% +$417 ﹤0.01% 340
2022
Q3 		$3K Buy
+35
New +$3.93K ﹤0.01% 319

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

China Universal Asset Management Company's ATRA Position: Q4 2023 in Review

China Universal Asset Management Company sold out of Atara Biotherapeutics (ATRA) in Q4 2023, closing a stake of 104 shares — an estimated $3.83K sold.

China Universal Asset Management Company first reported a position in ATRA in Q3 2022 and held it in 5 quarters. The position peaked at $3.83K in Q3 2023. 90 funds tracked by Wall St. Rank hold ATRA as of Q4 2023.

  • China Universal Asset Management Company reported no remaining Atara Biotherapeutics position as of Q4 2023 after selling out during the quarter.
  • China Universal Asset Management Company sold 104 Atara Biotherapeutics shares in Q4 2023, an estimated $3.83K.
  • China Universal Asset Management Company first reported a position in Atara Biotherapeutics in Q3 2022 and held it in 5 quarters.
  • China Universal Asset Management Company's Atara Biotherapeutics position peaked at $3.83K in Q3 2023.
  • 90 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2023.

Based on China Universal Asset Management Company's 13F filing for Q4 2023, filed 24 Jan 2024.